Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:49 2024-04-23 am EDT			5-day change	1st Jan Change
88.94 ^CHF	+1.81%		+4.64%	+4.80%

07:35am	Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy	DJ
07:20am	Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial	MT

NOVARTIS AG : Gets a Neutral rating from Deutsche Bank

September 13, 2021 at 05:38 am EDT

Emmanuel Papadakis from Deutsche Bank retains his Neutral opinion on the stock. The target price is unchanged and still at CHF 80.

Latest news about Novartis AG

Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy	01:35am	DJ
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial	01:20am	MT
Novartis Faces Lawsuit for Illegal Promotion of Asthma Drug as Preterm Labor Treatment	12:42am	MT
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients	11:54pm	MT
US Equity Markets Close Higher Tuesday	Apr. 23	MT
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	Apr. 23	MT
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment	Apr. 23	DJ
Novartis radioligand therapy Lutathera(R) FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	DJ
NOVARTIS : 2024 has started on a strong note; guidance upgraded	Apr. 23
Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock	Apr. 23	MT
Novartis’ Bumper Q1 Earnings Nudge Swiss Stocks Higher	Apr. 23	MT
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple...	Apr. 23
Corporate results bound the become the next catalyst for markets	Apr. 23
Dpa-AFX Overview: COMPANIES from 23.04.2024 - 15:15	Apr. 23	DP
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Apr. 23	MT
Trending : Novartis Shares Climb on Guidance Lift	Apr. 23	DJ
NOVARTIS AG : JP Morgan gives a Neutral rating	Apr. 23	ZD
Transcript : Novartis AG, Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
NOVARTIS AG : Barclays keeps a Sell rating	Apr. 23	ZD
Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated	Apr. 23	MT
European Midday Briefing: Stocks Buoyed by Strong Earnings, FTSE 100 Hits Fresh Record	Apr. 23	DJ
North American Morning Briefing : Stock Futures Rise, Tesla Earnings in Focus	Apr. 23	DJ
NOVARTIS : Oddo BHF confirms its recommendation on the share	Apr. 23	CF
Novartis AG Revise Earnings Guidance for the Year 2024	Apr. 23	CI
MORNING BID AMERICAS-Tanking Tesla reports, Europe business beats	Apr. 23	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-07-18 - Q2 2024 Earnings Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

97.67 USD

Average target price

107.6 USD

Spread / Average Target

+10.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+4.80%	199B
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+27.68%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+6.30%	217B
ROCHE HOLDING AG	-6.05%	204B
PFIZER, INC.	-8.58%	149B
AMGEN INC.	-4.99%	147B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Gets a Neutral rating from Deutsche Bank

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals